Anti-angiogenic effects of biotechnological therapies in rheumatic diseases

12Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

Abstract

Introduction: Angiogenesis plays a key role in the pathogenesis of numerous rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, and vasculitides. Therefore, the inhibition of pathological angiogenesis may be considered a useful therapeutical approach in these rheumatic diseases. Methods: This review article is based on a literature research about the role of biotechnological therapies in angiogenesis inhibition. Results and conclusions: Several evidences have demonstrated a role for biotechnological therapies in angiogenesis inhibition. Nevertheless, further research and clinical trials are needed to better quantify the real impact of biotechnological therapies on pathological angiogenesis.

Cite

CITATION STYLE

APA

Cantatore, F. P., Maruotti, N., Corrado, A., & Ribatti, D. (2017). Anti-angiogenic effects of biotechnological therapies in rheumatic diseases. Biologics: Targets and Therapy. Dove Medical Press Ltd. https://doi.org/10.2147/BTT.S143674

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free